Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other financing activities (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Other financing activities over the past 12 years, most recently at $478000.0 for Q4 2025.

  • Quarterly results put Other financing activities at $478000.0 for Q4 2025, up 101.98% from a year ago — trailing twelve months through Dec 2025 was $478000.0 (changed N/A YoY), and the annual figure for FY2025 was $478000.0, changed.
  • Other financing activities for Q4 2025 was $478000.0 at Viridian Therapeutics, Inc.\DE, up from -$207000.0 in the prior quarter.
  • Over the last five years, Other financing activities for VRDN hit a ceiling of $18.1 million in Q3 2022 and a floor of -$24.1 million in Q4 2024.
  • Median Other financing activities over the past 5 years was $218000.0 (2021), compared with a mean of $110615.4.
  • Peak annual rise in Other financing activities hit 4491.82% in 2021, while the deepest fall reached 527000.0% in 2021.
  • Viridian Therapeutics, Inc.\DE's Other financing activities stood at -$5.3 million in 2021, then crashed by 235.93% to -$17.7 million in 2022, then skyrocketed by 102.9% to $514000.0 in 2023, then tumbled by 4794.94% to -$24.1 million in 2024, then surged by 101.98% to $478000.0 in 2025.
  • The last three reported values for Other financing activities were $478000.0 (Q4 2025), -$207000.0 (Q3 2025), and $207000.0 (Q1 2025) per Business Quant data.